RTP Mobile Logo
Gastrointestinal Cancer Update, Issue 3, 2010
Released October 2010

Featuring interviews with Drs Axel Grothey, Jaffer A Ajani, Malcolm J Moore and Al B Benson III. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Colorectal cancer (CRC) is a common and potentially lethal type of cancer, and its clinical management is continuously evolving. Although “non-CRC” gastrointestinal (GI) tumors are less frequently encountered individually, the cancer-related deaths in that subcategory surpass those attributed to CRC. Published results from ongoing trials continuously lead to the emergence of novel biomarkers and new therapeutic targets and regimens, thereby altering existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Gastrointestinal Cancer Update utilizes one-on-one discussion with leading GI oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.

    LEARNING OBJECTIVES

    • Evaluate significant data presented at the ASCO 2010 Annual Meeting, and determine how the data may apply to the treatment of GI cancer.
    • Summarize key findings from clinical studies of emerging therapeutic regimens for pancreatic and biliary tract cancer.
    • Assess the role of molecular markers in optimizing therapeutic decisions for patients with early or advanced CRC.
    • Communicate to patients with metastatic CRC the benefits and risks of existing and emerging anti-VEGF and anti-EGFR biologic therapy.
    • Apply clinical trial results to integrate the use of chemotherapy with biologic agents, such as anti-HER2 and anti-VEGF agents, into the treatment of gastroesophageal cancer when appropriate.
    • Counsel appropriately selected patients with GI cancer about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Grothey had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr AjaniConsulting Agreements: Abraxis BioScience, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Sanofi-Aventis; Paid Research: ACT Biotech Inc, Bristol-Myers Squibb Company, Genta Inc, ImClone Systems Incorporated, Sanofi-Aventis, Taiho Pharmaceutical Co Ltd. Dr Moore Paid Research: ImClone Systems Incorporated. Dr BensonAdvisory Committee: Amgen Inc, Genomic Health Inc, Lilly USA LLC; Paid Research: Amgen Inc, Genentech BioOncology, Sanofi-Aventis.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.


    This program is supported by educational grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Genentech BioOncology, Genomic Health Inc and Sanofi-Aventis.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    October 2010
    Expiration date:
    October 2011

Acknowledge and close

Gastrointestinal Cancer Update, Issue 3, 2010
Released October 2010

Featuring interviews with Drs Axel Grothey, Jaffer A Ajani, Malcolm J Moore and Al B Benson III. (Text and Audio Content)